Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial.

Importance Sprifermin is under investigation as a disease-modifying osteoarthritis drug. Objective To evaluate the effects of sprifermin on changes in total femorotibial joint cartilage thickness in the more symptomatic knee of patients with osteoarthritis. Design, Setting, and Participants FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) was a 5-year, dose-finding, multicenter randomized clinical trial conducted at 10 sites. Eligible participants were aged 40 to 85 years with symptomatic, radiographic knee osteoarthritis and Kellgren-Lawrence grade 2 or 3. Enrollment began in July 2013 and ended in May 2014; the last participant visit occurred on May 8, 2017. The primary outcome at 2 years and a follow-up analysis at 3 years are reported. Interventions Participants were randomized to 1 of 5 groups: intra-articular injections of 100 μg of sprifermin administered every 6 months (n = 110) or every 12 months (n = 110), 30 μg of sprifermin every 6 months (n = 111) or every 12 months (n = 110), or placebo every 6 months (n = 108). Each treatment consisted of weekly injections over 3 weeks. Main Outcomes and Measures The primary end point was change in total femorotibial joint cartilage thickness measured by quantitative magnetic resonance imaging at 2 years. The secondary end points (of 15 total) included 2-year change from baseline in total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores. The minimal clinically important difference (MCID) is unknown for the primary outcome; for total WOMAC score in patients with hip and knee osteoarthritis, the absolute MCID is 7 U (95% CI, 4 to 10 U) and the percentage MCID is 14% (95% CI, 9% to 18%). Results Among 549 participants (median age, 65.0 years; 379 female [69.0%]), 474 (86.3%) completed 2-year follow-up. Compared with placebo, the changes from baseline to 2 years in total femorotibial joint cartilage thickness were 0.05 mm (95% CI, 0.03 to 0.07 mm) for 100 μg of sprifermin administered every 6 months; 0.04 mm (95% CI, 0.02 to 0.06 mm) for 100 μg of sprifermin every 12 months; 0.02 mm (95% CI, -0.01 to 0.04 mm) for 30 μg of sprifermin every 6 months; and 0.01 mm (95% CI, -0.01 to 0.03 mm) for 30 μg of sprifermin every 12 months. Compared with placebo, there were no statistically significant differences in mean absolute change from baseline in total WOMAC scores for 100 μg of sprifermin administered every 6 months or every 12 months, or for 30 μg of sprifermin every 6 months or every 12 months. The most frequently reported treatment-emergent adverse event was arthralgia (placebo: n = 46 [43.0%]; 100 μg of sprifermin administered every 6 months: n = 45 [41.3%]; 100 μg of sprifermin every 12 months: n = 50 [45.0%]; 30 μg of sprifermin every 6 months: n = 40 [36.0%]; and 30 μg of sprifermin every 12 months: n = 48 [44.0%]). Conclusions and Relevance Among participants with symptomatic radiographic knee osteoarthritis, the intra-articular administration of 100 μg of sprifermin every 6 or 12 months vs placebo resulted in an improvement in total femorotibial joint cartilage thickness after 2 years that was statistically significant, but of uncertain clinical importance; there was no significant difference for 30 μg of sprifermin every 6 or 12 months vs placebo. Durability of response also was uncertain. Trial Registration ClinicalTrials.gov Identifier: NCT01919164.

[1]  D J Hunter,et al.  Summary and recommendations of the OARSI FDA osteoarthritis Assessment of Structural Change Working Group. , 2011, Osteoarthritis and cartilage.

[2]  M. Karsdal,et al.  Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo , 2017, Journal of Translational Medicine.

[3]  G. Gold,et al.  OARSI Clinical Trials Recommendations: Hip imaging in clinical trials in osteoarthritis. , 2015, Osteoarthritis and cartilage.

[4]  C. Bombardier,et al.  Development of Multinational Definitions of Minimal Clinically Important Improvement and Patient Acceptable Symptomatic State in Osteoarthritis , 2015, Arthritis care & research.

[5]  D. Felson,et al.  Pre-radiographic osteoarthritic changes are highly prevalent in the medial patella and medial posterior femur in older persons: Framingham OA study. , 2014, Osteoarthritis and cartilage.

[6]  F Eckstein,et al.  Predictive and concurrent validity of cartilage thickness change as a marker of knee osteoarthritis progression: data from the Osteoarthritis Initiative. , 2017, Osteoarthritis and cartilage.

[7]  S. Reichenbach,et al.  All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study , 2011, BMJ : British Medical Journal.

[8]  L. Sharma,et al.  Breaking the Law of Valgus: the surprising and unexplained prevalence of medial patellofemoral cartilage damage , 2012, Annals of the rheumatic diseases.

[9]  T. Schnitzer,et al.  OARSI Clinical Trials Recommendations: Design, conduct, and reporting of clinical trials for knee osteoarthritis. , 2015, Osteoarthritis and cartilage.

[10]  Johanne Martel-Pelletier,et al.  Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation , 2011, Annals of the rheumatic diseases.

[11]  F. Eckstein,et al.  Intraarticular Sprifermin (Recombinant Human Fibroblast Growth Factor 18) in Knee Osteoarthritis: A Randomized, Double‐Blind, Placebo‐Controlled Trial , 2014, Arthritis & rheumatology.

[12]  L. Sharma,et al.  How do short-term rates of femorotibial cartilage change compare to long-term changes? Four year follow-up data from the osteoarthritis initiative. , 2012, Osteoarthritis and cartilage.

[13]  K. Brandt,et al.  Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs. , 2005, Arthritis and rheumatism.

[14]  C. Goldsmith,et al.  Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. , 1988, The Journal of rheumatology.

[15]  J. Raynauld,et al.  Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy : a randomised , double-blind , placebo-controlled pilot study using MRI , 2022 .

[16]  F Eckstein,et al.  OARSI Clinical Trials Recommendations: Knee imaging in clinical trials in osteoarthritis. , 2015, Osteoarthritis and cartilage.

[17]  D. Thompson,et al.  Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. , 2005, Osteoarthritis and cartilage.

[18]  Felix Eckstein,et al.  A Technique for Regional Analysis of Femorotibial Cartilage Thickness Based on Quantitative Magnetic Resonance Imaging , 2008, IEEE Transactions on Medical Imaging.

[19]  L. Sharma,et al.  Comparison of radiographic joint space width and magnetic resonance imaging for prediction of knee replacement: A longitudinal case-control study from the Osteoarthritis Initiative , 2016, European Radiology.

[20]  F Eckstein,et al.  Two year longitudinal change and test-retest-precision of knee cartilage morphology in a pilot study for the osteoarthritis initiative. , 2007, Osteoarthritis and cartilage.

[21]  G. R. Dodge,et al.  Sprifermin treatment enhances cartilage integration in an in vitro repair model , 2018, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[22]  Jeffrey B. Driban,et al.  Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial , 2017, JAMA.

[23]  B. Giraudeau,et al.  Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. , 2005, The Journal of rheumatology.

[24]  P Tugwell,et al.  OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. , 2008, Osteoarthritis and cartilage.

[25]  M. Karsdal,et al.  Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future. , 2016, Osteoarthritis and cartilage.

[26]  A Guermazi,et al.  What is the predictive value of MRI for the occurrence of knee replacement surgery in knee osteoarthritis? , 2013, Annals of the rheumatic diseases.

[27]  J. Jurvelin,et al.  A first-in-human, double-blind, randomised, placebo-controlled, dose ascending study of intra-articular rhFGF18 (sprifermin) in patients with advanced knee osteoarthritis. , 2016, Clinical and experimental rheumatology.

[28]  T. Vos,et al.  The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study , 2014, Annals of the rheumatic diseases.

[29]  M. Karsdal,et al.  Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix. , 2017, Osteoarthritis and cartilage.

[30]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[31]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2013, JAMA.

[32]  J. Raynauld,et al.  Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. , 2003, Arthritis and rheumatism.